Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre–T-DM1 era cohort study

Background: Adjuvant trastuzumab emtansine (T-DM1) is the standard treatment for HER2-positive early breast cancer (EBC) patients who do not achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Given the heterogeneity within this population, we analyzed long-term outcom...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ludovic Doucet, Camille Moreau-Bachelard, Laurent Mathiot, Olivier Kerdraon, Marie Robert, Julie Quintin, François Bocquet, Morgan Zenatri, Mario Campone, Jean-Sébastien Frenel
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-01-01
Series:	Cancer Treatment and Research Communications
Assuntos:	HER2-positive early breast cancer Pathologic complete response KATHERINE trial Trastuzumab emtansine
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S246829422500214X
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!